The Post Operative Nausea And Vomiting drugs in development market research report provides comprehensive information on the therapeutics under development for Post Operative Nausea And Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post Operative Nausea And Vomiting. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post Operative Nausea And Vomiting and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Post Operative Nausea And Vomiting by ten companies/universities/institutes. The top development phase for Post Operative Nausea And Vomiting is preclinical with four drugs in that stage. The Post Operative Nausea And Vomiting pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Post Operative Nausea And Vomiting pipeline products market are: Luxena Pharmaceuticals, Cellix Bio and Nanjing Zenkom Pharmaceutical.
The key targets in the Post Operative Nausea And Vomiting pipeline products market include 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3), D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2), and D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3).
The key mechanisms of action in the Post Operative Nausea And Vomiting pipeline product include D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist with four drugs in Pre-Registration. The Post Operative Nausea And Vomiting pipeline products include five routes of administration with the top ROA being Intravenous and two key molecule types in the Post Operative Nausea And Vomiting pipeline products market including Small Molecule, and Peptide.
Post Operative Nausea And Vomiting overview
Post Operative Nausea and Vomiting is one of the most common problems observed after chemo, anesthesia, and surgical interventions. Triggering of CTZ, vagal mucosal pathway, Neuronal pathways etc. when stimulated activates the sensation of vomiting. Nausea is defined as an unpleasant sensation while nausea is a forceful expulsion of even a small amount of upper gastrointestinal contents. Surgical factors, patient factors, medications, and intra and post operative factors result in PONV. Anti-emetics are primary chosen therapeutic strategy for treating nausea and vomiting. Parenteral nutrition to prevent dehydration. Ondansetron, Prochlorperazine, anti-cholinergic, dopamine antagonists are chosen.
For a complete picture of Post Operative Nausea And Vomiting’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
